Intensified Cytarabine Dose during Consolidation Therapy in AML Patients Under 65 Years Is Not Associated with Survival Benefit
Maher Hanoun(Essen University Hospital), Christoph Röllig(University Hospital Carl Gustav Carus), Mathias Haenel(Klinikum Chemnitz), Kerstin Schäfer-Eckhard(Nuremberg Hospital), Hermann Einsele(Universitätsklinikum Würzburg), Sebastian Scholl(Jena University Hospital), Björn Steffen(Goethe University Frankfurt), Carsten Müller‐Tidow(Heidelberg University), Hans Christian Reinhardt(German Cancer Research Center), Claudia D. Baldus(University Hospital Schleswig-Holstein), Martin Bornhaeuser(German Cancer Research Center), Dirk Niemann(Gemeinschaftsklinikum Mittelrhein), Tim H. Brümmendorf(National University Cancer Institute, Singapore), Johannes Kullmer(DIAKO), Andreas Neubauer(RWTH Aachen University), Edgar Jost(Universitätsklinikum Aachen), Leo Ruhnke(Krankenhaus Dresden-Friedrichstadt), Lars Fransecky, Sabrina Kraus(Universitätsklinikum Würzburg), Christoph Schliemann(University Hospital Münster), Ruth Seggewiss-Bernhard(Sozialstiftung Bamberg), Ulrich Kaiser(University of Applied Sciences Landshut), Uwe Platzbecker(National Center for Tumor Diseases), Stefan W. Krause(Universitätsklinikum Erlangen), Hubert Serve(Goethe University Frankfurt), Tim Sauer(Heidelberg University), Martin Kaufmann(Robert Bosch Hospital), Martin Göerner(Klinikum Bielefeld), Gerhard Held(Saarland University), Michael Krämer(University Hospital Carl Gustav Carus)
Cited by 0
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k